MAKE A CLEAR DIFFERENCE WITH OPZELURA

PRIMARY ENDPOINT

CLEAR OR ALMOST CLEAR RESULTS (IGA-TS*) AT WEEK 81-3

Line chart shows the percentage of patients who achieved IGA-TS by week 8 of the TRuE-AD1 and TRuE-AD2 clinical trials: 53.8% with OPZELURA vs 15.1% with vehicle and 51.3% with OPZELURA vs 7.6% with vehicle, respectively; P<0.0001.
Line chart shows the percentage of patients who achieved IGA-TS by week 8 of the TRuE-AD1 and TRuE-AD2 clinical trials: 53.8% with OPZELURA vs 15.1% with vehicle and 51.3% with OPZELURA vs 7.6% with vehicle, respectively; P<0.0001.

Adapted from Papp K et al. doi:10.17632/ffx6nd5zyb.1. Licensed under CC BY 4.0.

>50% of patients achieved
  • clear or almost clear skin with ≥2-point improvement from baseline at week 81

  • clear or almost clear skin with ≥2-point improvement from baseline at week 81

Patient Sarah-Beth-2

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.1

BID=twice daily; IGA=Investigator’s Global Assessment;
IGA-TS=Investigator’s Global Assessment Treatment Success.

Patient Sarah-Beth-2

See the before and after difference >

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized,
double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085. 3. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1.